Literature DB >> 17314171

Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.

David H Nguyen1, Suryaram Gummuluru, Jianming Hu.   

Abstract

The APOBEC3 family of mammalian cytidine deaminases, including APOBEC3G (A3G), has been shown to function as innate antiviral factors against retroviruses and can also suppress the replication of the hepatitis B virus (HBV). The mechanism by which A3G inhibits HBV replication remains to be elucidated. In this study, we show that the inhibitory effect of APOBEC3 proteins on HBV replication was mainly at the DNA level, with only a minor effect on viral RNA packaging. The anti-HBV effect of A3G was independent of the DNA-editing function, and the mode of inhibition was not due to HBV DNA degradation. The editing-independent antiviral activity of A3G could target DNA-RNA hybrids as well as single-stranded DNA. Finally, we show that there was a preferential decrease in the accumulation of longer minus-strand DNA by A3G, compared to the shorter minus-strand DNA, and suggest that A3G exerts its inhibitory effect at very early stages during viral reverse transcription.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314171      PMCID: PMC1900192          DOI: 10.1128/JVI.02510-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis.

Authors:  G H Wang; C Seeger
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

2.  APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.

Authors:  Timothy M Alce; Waldemar Popik
Journal:  J Biol Chem       Date:  2004-06-23       Impact factor: 5.157

3.  Novel mechanism for reverse transcription in hepatitis B viruses.

Authors:  G H Wang; C Seeger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

4.  Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity.

Authors:  G Radziwill; W Tucker; H Schaller
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

5.  Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate.

Authors:  J Summers; W S Mason
Journal:  Cell       Date:  1982-06       Impact factor: 41.582

6.  Specific hepatitis B virus minus-strand DNA synthesis requires only the 5' encapsidation signal and the 3'-proximal direct repeat DR1.

Authors:  A Rieger; M Nassal
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.

Authors:  Rodolphe Suspène; Peter Sommer; Michel Henry; Stéphane Ferris; Denise Guétard; Sylvie Pochet; Ann Chester; Naveenan Navaratnam; Simon Wain-Hobson; Jean-Pierre Vartanian
Journal:  Nucleic Acids Res       Date:  2004-04-30       Impact factor: 16.971

8.  Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.

Authors:  Evguenia S Svarovskaia; Hongzhan Xu; Jean L Mbisa; Rebekah Barr; Robert J Gorelick; Akira Ono; Eric O Freed; Wei-Shau Hu; Vinay K Pathak
Journal:  J Biol Chem       Date:  2004-06-20       Impact factor: 5.157

9.  Cytidine deamination of retroviral DNA by diverse APOBEC proteins.

Authors:  Kate N Bishop; Rebecca K Holmes; Ann M Sheehy; Nicholas O Davidson; Soo-Jin Cho; Michael H Malim
Journal:  Curr Biol       Date:  2004-08-10       Impact factor: 10.834

10.  A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA.

Authors:  M Junker-Niepmann; R Bartenschlager; H Schaller
Journal:  EMBO J       Date:  1990-10       Impact factor: 11.598

View more
  85 in total

1.  Maturation-associated destabilization of hepatitis B virus nucleocapsid.

Authors:  Xiuji Cui; Laurie Ludgate; Xiaojun Ning; Jianming Hu
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

Review 2.  Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.

Authors:  Jieliang Chen; Zhenghong Yuan
Journal:  Virol Sin       Date:  2014-01-20       Impact factor: 4.327

Review 3.  Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B.

Authors:  Bidisha Mitra; Roshan J Thapa; Haitao Guo; Timothy M Block
Journal:  Antiviral Res       Date:  2018-08-24       Impact factor: 5.970

4.  In vitro epsilon RNA-dependent protein priming activity of human hepatitis B virus polymerase.

Authors:  Scott A Jones; Rajeev Boregowda; Thomas E Spratt; Jianming Hu
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

5.  Correlation of APOBEC3G expression with liver function indexes of patients with chronic hepatitis B and comparison in chronic hepatitis B, liver cirrhosis and liver cancer.

Authors:  Lina Ni; Chuanbao Li; Yingbo Li
Journal:  Oncol Lett       Date:  2020-01-24       Impact factor: 2.967

6.  Unveiling the roles of HBV polymerase for new antiviral strategies.

Authors:  Daniel N Clark; Jianming Hu
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

7.  Protein-primed terminal transferase activity of hepatitis B virus polymerase.

Authors:  Scott A Jones; Jianming Hu
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

Review 8.  Human cellular restriction factors that target HIV-1 replication.

Authors:  Klaus Strebel; Jeremy Luban; Kuan-Teh Jeang
Journal:  BMC Med       Date:  2009-09-16       Impact factor: 8.775

9.  The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.

Authors:  Nzovu K Ulenga; Abdoulaye Dieng Sarr; Donald Hamel; Jean-Louis Sankale; Souleymane Mboup; Phyllis J Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2008-10       Impact factor: 2.205

10.  Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.

Authors:  Scott A Jones; Eisuke Murakami; William Delaney; Phillip Furman; Jianming Hu
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.